September 26, 2019 / 8:17 PM / 25 days ago

BRIEF-Xoma Acquires Royalty Interest Position In Six Clinical-Stage Assets

Sept 26 (Reuters) - XOMA Corp:

* XOMA ACQUIRES ROYALTY INTEREST POSITION IN SIX CLINICAL-STAGE ASSETS

* XOMA CORP - ACQUIRED A ROYALTY INTEREST IN SIX CLINICAL-STAGE ASSETS TARGETING ADENOSINE PATHWAY FOR $10.0 MILLION FROM PALOBIOFARMA S.L.

* XOMA CORP - WILL RECEIVE LOW SINGLE-DIGIT ROYALTIES ON FUTURE SALES OF THESE SIX ADENOSINE RECEPTOR ASSETS

* XOMA - CO HAS ACQUIRED A ROYALTY INTEREST IN NIR178, THAT IS BEING DEVELOPED BY NOVARTIS AS A NOVEL CHECKPOINT INHIBITOR FOR TREATMENT OF SOLID TUMORS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below